Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000668588 | SCV000793215 | pathogenic | Lysosomal acid lipase deficiency | 2017-08-04 | criteria provided, single submitter | clinical testing | |
Invitae | RCV001376570 | SCV001200176 | pathogenic | Wolman disease | 2023-11-20 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Phe228Leufs*13) in the LIPA gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in LIPA are known to be pathogenic (PMID: 23485521). This variant is present in population databases (rs770074196, gnomAD 0.007%). This premature translational stop signal has been observed in individuals with cholesteryl ester storage disease (PMID: 10562460, 10627498). ClinVar contains an entry for this variant (Variation ID: 553192). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. Experimental studies have shown that this premature translational stop signal affects LIPA function (PMID: 29196158). For these reasons, this variant has been classified as Pathogenic. |
Natera, |
RCV000668588 | SCV001453546 | pathogenic | Lysosomal acid lipase deficiency | 2020-09-16 | no assertion criteria provided | clinical testing |